Evidence map›Paper›PMID 31330989›Full record

ArticleCancers2019

Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer.

Dennis Wang, Nhu-An Pham, Timothy M Freeman, Vibha Raghavan, Roya Navab, Jonathan Chang, Chang-Qi Zhu, Dalam Ly, Jiefei Tong, Bradly G Wouters and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Connexin-Pannexin duality in glioblastoma.Cell and tissue research · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Dennis WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. dennis.wang@sheffield.ac.uk.ORCID 0000-0003-0068-1005
Nhu-An PhamPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Timothy M FreemanNIHR Sheffield Biomedical Research Centre, University of Sheffield, Sheffield S10 2HQ, UK.ORCID 0000-0002-4497-681X
Vibha RaghavanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Roya NavabPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Jonathan ChangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.ORCID 0000-0002-1533-712X
Chang-Qi ZhuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Dalam LyToronto General Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0002-1177-0225
Jiefei TongProgram in Molecular Structure and Function, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.
Bradly G WoutersPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Melania PintiliePrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Michael F MoranProgram in Molecular Structure and Function, Hospital for Sick Children, Toronto, ON M5G 0A4, Canada.ORCID 0000-0003-4878-9285
Geoffrey LiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Frances A ShepherdPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Ming-Sound TsaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. ming.tsao@uhn.ca.
University Health Network · CAHospital for Sick Children · CAUniversity of Sheffield · GB

Funding

Canadian Institutes of Health Research FDN-148395National Institute for Health Research NIHR Sheffield Biomedical Research Centre
6 · The paper itself

Abstract

The burden of somatic mutations and neoantigens has been associated with improved survival in cancer treated with immunotherapies, especially non-small cell lung cancer (NSCLC). However, there is uncertainty about their effect on outcome in early-stage untreated cases. We posited that the burden of mutations in a specific set of genes may also contribute to the prognosis of early NSCLC patients. From a small cohort of 36 NSCLC cases, we were able to identify somatic mutations and copy number alterations in 865 genes that contributed to patient overall survival. Simply, the number of altered genes (NAG) among these 865 genes was associated with longer disease-free survival (hazard ratio (HR) = 0.153,

Indexed as

cancer genomicscancer immunologycopy numbermutation burdenoncogenic pathwayspatient-derived xenograftpatient stratificationprognosis

Identifiers

PMID31330989
PMCPMC6678704
OpenAlexW2963393430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.